Viridian Therapeutics, Inc. (0K1R.L)
USD 19.62
(-7.91%)
USD 19.62
(-7.91%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1 Million USD | -199.12% |
| 2022 | 1.01 Million USD | -56.59% |
| 2021 | 2.34 Million USD | 108.6% |
| 2020 | -27.25 Million USD | 3.81% |
| 2019 | -28.33 Million USD | -28.58% |
| 2018 | -22.03 Million USD | -41.07% |
| 2017 | -15.62 Million USD | -2079.72% |
| 2016 | 789 Thousand USD | 1095.45% |
| 2015 | 66 Thousand USD | -93.87% |
| 2014 | 1.07 Million USD | -40.74% |
| 2013 | 1.81 Million USD | 33.26% |
| 2012 | 1.36 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -273 Thousand USD | 1.8% |
| 2024 Q2 | -5.71 Million USD | -1994.87% |
| 2023 Q2 | -360 Thousand USD | -236.45% |
| 2023 FY | -1 Million USD | -199.12% |
| 2023 Q3 | -263 Thousand USD | 26.94% |
| 2023 Q4 | -278 Thousand USD | -5.7% |
| 2023 Q1 | -107 Thousand USD | 99.73% |
| 2022 Q4 | -39.21 Million USD | -87.4% |
| 2022 Q2 | -21.45 Million USD | -28331.58% |
| 2022 Q1 | 76 Thousand USD | 118.18% |
| 2022 FY | 1.01 Million USD | -56.59% |
| 2022 Q3 | -20.92 Million USD | 2.48% |
| 2021 Q2 | -11.47 Million USD | 7.12% |
| 2021 Q4 | -418 Thousand USD | 94.72% |
| 2021 FY | 2.34 Million USD | 108.6% |
| 2021 Q1 | -12.35 Million USD | 18.72% |
| 2021 Q3 | -7.91 Million USD | 31.04% |
| 2020 Q2 | -3.66 Million USD | 30.46% |
| 2020 Q3 | -3.11 Million USD | 15.19% |
| 2020 FY | -27.25 Million USD | 3.81% |
| 2020 Q4 | -15.2 Million USD | -388.59% |
| 2020 Q1 | -5.27 Million USD | 4.73% |
| 2019 Q3 | -8.33 Million USD | -36.93% |
| 2019 Q1 | -8.37 Million USD | -8.0% |
| 2019 FY | -28.33 Million USD | -28.58% |
| 2019 Q4 | -5.53 Million USD | 33.55% |
| 2019 Q2 | -6.08 Million USD | 27.38% |
| 2018 FY | -22.03 Million USD | -41.07% |
| 2018 Q4 | -7.75 Million USD | -20.19% |
| 2018 Q3 | -6.45 Million USD | -4.23% |
| 2018 Q2 | -6.19 Million USD | -280.17% |
| 2018 Q1 | -1.62 Million USD | 57.2% |
| 2017 Q1 | -3.65 Million USD | -5815.63% |
| 2017 Q2 | -4.76 Million USD | -30.37% |
| 2017 Q3 | -3.38 Million USD | 28.98% |
| 2017 Q4 | -3.8 Million USD | -12.37% |
| 2017 FY | -15.62 Million USD | -2079.72% |
| 2016 FY | 789 Thousand USD | 1095.45% |
| 2016 Q1 | 189 Thousand USD | -6.9% |
| 2016 Q2 | 246 Thousand USD | 30.16% |
| 2016 Q3 | 290 Thousand USD | 17.89% |
| 2016 Q4 | 64 Thousand USD | -77.93% |
| 2015 FY | 66 Thousand USD | -93.87% |
| 2015 Q4 | 203 Thousand USD | 367.11% |
| 2015 Q2 | 56 Thousand USD | 148.7% |
| 2015 Q1 | -115 Thousand USD | 54.95% |
| 2015 Q3 | -76 Thousand USD | -235.71% |
| 2014 Q4 | -255.26 Thousand USD | -159.44% |
| 2014 FY | 1.07 Million USD | -40.74% |
| 2014 Q1 | 427.4 Thousand USD | -39.11% |
| 2014 Q2 | 597.84 Thousand USD | 39.88% |
| 2014 Q3 | 429.46 Thousand USD | -28.16% |
| 2013 Q1 | 470.42 Thousand USD | 0.0% |
| 2013 FY | 1.81 Million USD | 33.26% |
| 2013 Q4 | 701.98 Thousand USD | 159.62% |
| 2013 Q3 | 270.38 Thousand USD | -45.91% |
| 2013 Q2 | 499.85 Thousand USD | 6.26% |
| 2012 FY | 1.36 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 100.745% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 100.419% |
| Codexis, Inc. | 57.33 Million USD | 101.758% |
| Organovo Holdings, Inc. | -5.38 Million USD | 81.295% |